TheraVab Biosciences Announces Exclusive Option to License Engineered Receptor Immunobiotherapy for the Treatment of Neu (Issue Wire)

TheraVab Biosciences Announces Exclusive Option to License Engineered Receptor Immunobiotherapy for the Treatment of Neu

TheraVab Biomedics Pte. Ltd., a pre-clinical stage immunotherapy company that aims at reversal of the inflammatory processes that lead to cancers, neurodegenerative ailments and cardiovascular disorders, announced that it has entered into an agreement with the University of Florida Research Foundation for the exclusive option to license decoy receptor technology for the development of an immunotherapy targeting neuroinflammatory diseases including Parkinson’s (PD) and Alzheimer’s (AD) diseases.

Jim O’Connell, assistant vice president of UF Innovate, the technology commercialization arm of the University of Florida, commented, “It is very gratifying to our research group that TheraVab is taking the lead in commercializing our engineered receptor technology and to see that our scientific discoveries may soon be available to the public and provide a significant positive impact on global health.”

Learn more about TheraVab Biosciences Announces Exclusive Option to License Engineered Receptor Immunobiotherapy for the Treatment of Neu.
X